Navigation Links
University of Kentucky Medical Center Transplants State's 1st SynCardia Total Artificial Heart Patient
Date:9/13/2012

TUCSON, Ariz., Sept. 13, 2012 /PRNewswire/ -- SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that University of Kentucky (UK) Medical Center has successfully transplanted its first patient to receive the SynCardia temporary Total Artificial Heart. Zack Poe, 21, received his matching donor heart in July after five months of life with the Total Artificial Heart.

(Photo: http://photos.prnewswire.com/prnh/20120913/LA73638)

"When we first met Zack, we knew that he was the perfect candidate to receive the Total Artificial Heart as a bridge to transplant," said Dr. Charles Hoopes, director of the UK Transplant Center. "The Total Artificial Heart worked exactly as we had planned, and it allowed Zack to gain back his strength before receiving an appropriate donor heart."

Zack was first diagnosed with heart failure in January, when an echocardiogram revealed that his ejection fraction -- a measurement of how much blood the heart pumps out to the body during each beat -- was less than 10 percent. He was referred to UK Medical Center for advanced treatment options, and about a week and a half after his initial diagnosis, his liver began to fail.

In order to save Zack's life, UK Medical Center completed SynCardia's four-phase certification program in a record 25 days. Zach was implanted with the Total Artificial Heart on Feb. 10. Less than a month later, on March 5, he was discharged from the hospital to wait for a matching donor heart at home with his family using the Freedom® portable driver.

"The transplant team here at UK is second to none, and patients like Zack are living proof," said Dr. Jay Zwischenberger, surgeon-in-chief at UK HealthCare. "The fact that Zack and his family did not have to leave the state for treatment shows the great strides UK HealthCare has made in our ability to provide care for Kentuckians with even the most complex health issues."

Weighing 13.5 pounds, the Freedom portable driver is the world's first wearable power supply for the SynCardia Total Artificial Heart. The Freedom driver is CE approved for use in Europe and undergoing an FDA-approved Investigational Device Exemption (IDE) clinical study in the U.S. On April 24, SynCardia completed the minimum enrollment required by the clinical study.

View news coverage of Zack's transplant
Read press release from UK Medical Center

Like SynCardia on Facebook
Follow SynCardia on Twitter – @SynCardia
Connect with SynCardia on LinkedIn

CAUTION – The Freedom portable driver is an investigational device, limited by United States law to investigational use.

About the SynCardia temporary Total Artificial Heart

SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, SynCardia's Total Artificial Heart is currently approved as a bridge to transplant for people dying from end-stage biventricular heart failure. There have been more than 1,000 implants of the Total Artificial Heart, accounting for more than 270 patient years of life.

Similar to a heart transplant, SynCardia's Total Artificial Heart replaces both failing heart ventricles and the four heart valves, eliminating the symptoms and source of end-stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers. It is the only device that provides immediate, safe blood flow of up to 9.5 liters per minute through each ventricle. This high volume of safe blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.

SynCardia Wins Two Gold Stevies® at 2012 American Business Awards

On June 18, 2012, SynCardia was honored with two Gold Stevie® Awards at the 10th Annual American Business Awards. SynCardia won "Company of the Year – Health Products and Services" and "Most Innovative Company of the Year – up to 100 Employees." See the full list of SynCardia Awards & Recognition, which includes accolades from Forbes, Fast Company and more.


'/>"/>
SOURCE SynCardia Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Islet Sciences Announces Exclusive License Agreement with the University of California (UCLA) to Commercialize Small Molecules for Islet Expansion
2. University of California, San Francisco (UCSF) Selects Conflict of Interest Management System
3. OncoSec Secures License for Electroporation Intellectual Property from University of South Florida
4. Islet Sciences Announces Exclusive License Agreement with Winthrop University Hospital to Commercialize a Beta Cell Loss Measurement Technology in Diabetes
5. First Evidence that Adipose Stem Cell-Based Critical Limb Ischemia Treatment is Safe & Effective is published in Circulation Journal by Lead Investigator Dr. Han Cheol Lee of Pusan National University
6. University of Miami study finds RBAC to possess promising immunomodulating effects with respect to natural killer cell and cytokine activity
7. Northwestern University Joins VIVO Network with Elseviers SciVal Experts
8. Chicago Celebrates First Informatics Week, Co-Chaired by Intelligent Medical Objects and Northwestern University
9. Worlds smallest semiconductor laser created by University of Texas scientists
10. Genetics Policy Institute (GPI) Collaborates on Second Midwest Conference on Stem Cell Biology and Therapy, Oct. 5-7 at Oakland University
11. University of Utah physicists invent spintronic LED
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... Research and Markets has announced the addition of the ... The global biomarkers market has ... The market is expected to grow at a five-year compound annual ... $50.6 billion in 2015 to $96.6 billion in 2020. ... to 2020) are discussed. As well, new products approved in 2013 ...
(Date:6/22/2016)... LOS ANGELES , June 22, 2016   ... an SNNLive Video Interview with Dr. Nader Pourhassan ... a biotechnology company focused on the clinical development and ... and prevention of HIV infection, according to the company,s ... was recorded on Tuesday, June 7 th , 2016, ...
(Date:6/22/2016)... DIEGO , June 22, 2016   ViaCyte, ... first pluripotent stem cell-derived islet replacement therapy for the ... presentations at ISSCR 2016 Annual Meeting.  ISSCR 2016, the ... to 25th at Moscone West in San Francisco.  ... of the presentations are as follows:Event: , Focus Session: ...
(Date:6/22/2016)... (PRWEB) , ... June 22, 2016 , ... ... at placing a spotlight on immigrant achievements and contributions to North Texas and ... most important contributors from the immigrant community to the civic and economic vitality ...
Breaking Biology Technology:
(Date:6/16/2016)... June 16, 2016 The ... expected to reach USD 1.83 billion by 2024, ... Research, Inc. Technological proliferation and increasing demand in ... expected to drive the market growth. ... The development of advanced multimodal techniques for ...
(Date:6/3/2016)... LONDON , June 3, 2016 /PRNewswire/ ... Transport Management) von Nepal ... ,Angebot und Lieferung hochsicherer geprägter Kennzeichen, einschließlich ... weltweit führend in der Produktion und Implementierung ... an der Ausschreibung im Januar teilgenommen, aber ...
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the medical ... premium product recently added to the range of products distributed by Ampronix. ... ... ... Ampronix News ...
Breaking Biology News(10 mins):